Prospective observational study of baloxavir marboxil in adults and adolescents with uncomplicated influenza from China

Figures

• 

  FIGURE 1. Duration of fever and influenza-related symptoms. (A) Duration of fever in the baloxavir group and oseltamivir group (P < 0.001). (B) Duration of fever in male patients between the baloxavir and oseltamivir groups (P < 0.001). (C) Duration of fever in female patients between the baloxavir and oseltamivir groups (P = 0.005). (D) Duration of symptoms in both treatment groups (P = 0.167). (E) Duration of symptoms in male patients between the baloxavir and oseltamivir groups (P = 0.752). (F) Duration of symptoms in female patients between the baloxavir and oseltamivir groups (P = 0.053).

• 

  FIGURE 2. Subgroup analysis of the duration of fever and symptoms. (A) Duration of fever in patients with body temperature >38.5 and ≤38.5°C. (B) Duration of fever in patients with >10 and ≤10 mg/L CRP. (C) Duration of symptoms in patients with baseline monocytes <0.5 × 109 and ≥ 0.5 × 109/L. (D) Duration of symptoms between male and female patients.

• 

  FIGURE 3. Changes in health-related quality of life in the two treatment groups. (A–E) Mobility, self-care, usual activities, pain/discomfort, and anxiety/depression scores of the two groups on day 7. (F) VAS score of both treatment groups. (G) Correlation between severity score of symptoms and VAS score (r = –0.340, P < 0.001). (H) Correlation between monocyte counts and VAS score (r = 0.180, P = 0.032). (I) Correlation between age and VAS score (r = 0.158, P = 0.027).

• 

  FIGURE 4. Changes in lymphocyte counts in the two treatment groups. (A) Lymphocyte counts on day 7 compared to baseline in both groups. (B) CD4+ T cell counts on day 7 compared to baseline in both groups. (C) CD8+ T cell counts on day 7 compared to baseline in both groups. (D) CD19+ B cell counts on day 7 compared to baseline in both groups. (E) CD56+ NK cell counts on day 7 compared to baseline in both groups. (F) CD4/CD8 ratio on day 7 compared to baseline in both groups.

• 

  FIGURE 5. Changes in virological status in two treatment groups. (A) Influenza antigen rapid test results on day 3 in both groups. (B) Viral load on day 3 compared with day 1 in both groups. (C) Mean age of patients tested negative and positive for viral RNA on day 3. (D) Baseline monocyte counts in patients tested negative and positive for viral RNA on day 3 in both groups. (E) Correlation between lymphocyte counts and viral load at baseline. (F) Correlation between lymphocyte counts at baseline and viral load on day 3.

• 

  FIGURE 6. Viral PA subunit sequences before and after baloxavir treatment. We observed some differences in the PA subunit between the Guangzhou influenza virus strain in 2022 and the A/Darwin/6/2021 strain recommended by the WHO for the influenza vaccine. Especially, in one patient (1/7), we observed a mutation from cysteine to serine at position 384 (pa C384S) after baloxavir treatment.